Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CKS1B | P61024 | 2/20 | 0.51 |
| ▸ | SKP1 | P63208 | 2/20 | 0.51 |
| ▸ | SKP2 | Q13309 | 2/20 | 0.51 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | GBA1 | P04062 | 1/20 | 0.45 |
| ▸ | GPR119 | Q8TDV5 | 10/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20163062 | 0.84 | CKS1B (0.52) | CKS1BSKP1SKP2MAP4K4MAPT | |
| SCHEMBL389963 | 0.83 | SMN1; SMN2 (0.43) | MAPTALDH1A1LMNAKDM4EMEN1 | |
| SCHEMBL31704489 | 0.82 | CKS1B (0.47) | CKS1BSKP1SKP2MAP4K4MAPT | |
| SCHEMBL17541646 | 0.78 | HRH3 (0.55) | CKS1BSKP1SKP2MAP4K4MAPT | |
| SCHEMBL2734028 | 0.78 | ALDH1A1 (0.60) | MAPTALDH1A1LMNAKDM4EKMT2A | |
| SCHEMBL461584 | 0.77 | CKS1B (0.62) | CKS1BSKP1SKP2MAP4K4MAPT | |
| SCHEMBL21796663 | 0.76 | GPR119 (0.56) | CKS1BSKP1SKP2MAP4K4MAPT | |
| SCHEMBL23560770 | 0.76 | CKS1B (0.57) | CKS1BSKP1SKP2MAP4K4MAPT | |
| SCHEMBL22873660 | 0.76 | GPR119 (0.58) | CKS1BSKP1SKP2MAP4K4MAPT | |
| SCHEMBL4524210 | 0.76 | CKS1B (0.57) | CKS1BSKP1SKP2MAP4K4MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8101618-B2 | 1,4-substituted piperazine derivatives | MSD K.K. (JP) | 2012-01-24 | — | — | US | disclosed |
| US-20090062293-A1 | 1,4-Substituted Piperazine Derivatives | MSD K.K. (JP) | 2009-03-05 | — | — | US | disclosed |
| EP-1870401-A1 | 1,4-SUBSTITUTED PIPERAZINE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-12-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062293-A1 | 1,4-Substituted Piperazine Derivatives | GRIN1, GRM1, GRIN2C | CKS1B 2830/4885SKP1 2025/4885SKP2 3286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.